Aplogan A, Batchassi E, Yakoua Y, Croisier A, Aleki A, Schlumberger M, Molina S, Sidatt M, Kaninda A V
Sante. 1997 Nov-Dec;7(6):384-90.
Neisseria meningitidis is responsible for high levels of morbidity and mortality in the developing countries of the African meningitis belt. There are frequent meningococcal meningitis epidemics in this region affecting almost 1,000 people in every 100,000 (1%). Epidemics generally occur during the dry season but the interval between epidemics is variable (between 2 and 25 years). The reasons for these recurrent epidemics are unclear. There is a safe and effective polysaccharide vaccine against meningococci A and C. Unfortunately, the immunity it provides decreases with time, especially in young children (aged less than 5 years) and it is thus not included in the Expanded Program on Immunization (EPI). WHO recommends mass vaccination using a threshold approach. This control strategy is effective if vaccination begins very soon after the threshold is crossed. There was an outbreak of group A meningococcal meningitis in the Savanes region of northern Togo in December 1996. The national surveillance system put out an alert and control measures were implemented. These involved improvement of the surveillance system, and containment immunization in villages for early cases followed by a mass immunization campaign in the entire region, distribution of oily chloramphenicol and decentralized case management. The target population for mass vaccination included everyone older than 6 months of age living in the Savanes region. The aim was to vaccinate at least 80% of the target population. There were 2,992 cases of meningitis reported in the Savanes region between December 1996 and May 1997 (in a population of about 500,000). This gives a cumulative incidence rate of 581 per 100,000 population. The epidemic was bimodal, with the first peak in the number of cases occurring at the end of January and the second peak in March. There were 60,700 vaccinations in two of the four districts of the region in December and January, as part of the containment strategy and 346,469 vaccinations in the four districts of the region during February, as part of the mass vaccination campaign. By the end of the mass campaign, 67.3% of the target population in the region as a whole had been vaccinated, with 61% vaccinated in the Kpendjal district and 78% in the Oti district. There was an increase in the number of cases 2 weeks after the end of the mass vaccination campaign. This was attributed to the inadequate level of vaccination achieved. Only 52% of the urban population of Dapaong were vaccinated. The national surveillance system put out an alert early in the epidemic. The intervention was planned and adapted according to the progression of the epidemic, and national and international efforts were well coordinated. This emphasizes the importance of a rapid reaction from the surveillance system and of the choice of strategy for dealing with meningitis epidemics in sub-Sahelian Africa.
脑膜炎奈瑟菌在非洲脑膜炎带的发展中国家导致了高发病率和高死亡率。该地区频繁出现脑膜炎球菌性脑膜炎疫情,每10万人中约有1000人(1%)受到影响。疫情通常发生在旱季,但疫情之间的间隔时间不一(2至25年)。这些反复出现疫情的原因尚不清楚。有一种针对A群和C群脑膜炎球菌的安全有效的多糖疫苗。不幸的是,它提供的免疫力会随着时间下降,尤其是在幼儿(5岁以下)中,因此未被纳入扩大免疫规划(EPI)。世卫组织建议采用阈值方法进行大规模疫苗接种。如果在超过阈值后很快开始接种疫苗,这种控制策略是有效的。1996年12月,多哥北部萨瓦内地区爆发了A群脑膜炎球菌性脑膜炎。国家监测系统发出警报并实施了控制措施。这些措施包括改进监测系统,对早期病例在村庄进行围堵免疫,随后在整个地区开展大规模免疫运动,分发油性氯霉素以及分散式病例管理。大规模疫苗接种的目标人群包括居住在萨瓦内地区所有6个月以上的人。目标是为至少80%的目标人群接种疫苗。1996年12月至1997年5月期间,萨瓦内地区报告了2992例脑膜炎病例(该地区人口约50万)。这给出的累积发病率为每10万人口581例。疫情呈双峰型,病例数的第一个高峰出现在1月底,第二个高峰出现在3月。作为围堵策略的一部分,该地区四个区中的两个区在12月和1月进行了60700次接种,作为大规模疫苗接种运动的一部分,2月在该地区四个区进行了346469次接种。到大规模接种运动结束时,整个地区67.3%的目标人群接种了疫苗,其中孔贾尔区为61%,奥蒂区为78%。大规模疫苗接种运动结束2周后病例数有所增加。这归因于接种水平不足。达庞的城市人口中只有52%接种了疫苗。国家监测系统在疫情早期发出了警报。干预措施根据疫情进展进行规划和调整,国家和国际努力得到了很好的协调。这强调了监测系统快速反应以及在萨赫勒以南非洲应对脑膜炎疫情时选择策略的重要性。